ClinicalTrials.gg
RecruitingNCT06375031Updated May 21, 2024

Comparison of HR011408 and NovoRapid® in Subjects With Diabetics

A Phase 1 interventional study of HR011408 injection; HR011408 injection Placebo and NovoRapid®; HR011408 injection Placebo in Diabetes, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2024-05-21.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Diabetes Mellitus by Jiangsu HengRui Medicine Co., Ltd. — 4 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
7th of 13
30 · median 30
Started
2024
with 1 other
Phase 1
13 of 13
4 open now
Registered
9th of 13
by date

Among the 13 studies in Diabetes Mellitus by Jiangsu HengRui Medicine Co., Ltd., this one is the 7th largest by planned enrollment, is one of 2 that started in 2024, is one of 13 in phase 1, and was the 9th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

4 of the 13 studies in Diabetes Mellitus by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Diabetes Mellitus by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

The objective of the study is to compare the pharmacokinetics and pharmacodynamics between HR011408 and NovoRapid® in Subjects with Diabetics.

03

Conditions studied

  • Diabetes

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects had to meet all the following criteria to enrol this study
  1. Male or female aged 18-64 years (both inclusive);
  2. 18.5-35.0 kg/m2 (both inclusive);
  3. Diagnosed with type 1 diabetes or type 2 diabetes≥ 12 months at screening;
  4. ≤9.0% by local laboratory at screening;
  5. Current treatment with any basal-bolus insulin regimen or continuous subcutaneous insulin infusion(CSII) for ≥ 8 weeks. Patients with type 2 diabetes can also take metformin but require a stable metformin dose for ≥8 weeks;
  6. Current total daily insulin treatment \< 1.2 U/kg/day, and total daily bolus insulin treatment ≥ 0.3 U/kg/day and \< 0.7 U/kg/day.

Exclusion criteria

Exclusion Criteria:

  • Subjects who meet any of the following criteria will be excluded from this study.
  1. The following laboratory or ancillary abnormalities were present from screening until randomization:
  1. Poor blood pressure control, defined as systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg.
  1. Subject has any history or evidence meet the following diseases or conditions:
  1. have had severe hypoglycaemia episodes within 6 months before screening as judged by the investigator.
  2. Have hospitalization due to diabetic ketoacidosis or hyperglycaemic hyperosmolar state within 6 months prior to screening;
  3. Proliferative retinopathy, maculopathy, and/or severe neuropathy, in particular autonomic neuropathy, as judged by the investigator.
  1. Previous and anticipated concomitant treatments:
  1. Not able or willing to refrain from any use of herbal products and non-routine vitamins within 14 days or within 5 half-lives (whichever is longer), and routine vitamins within 48 hours prior to trial product administration
  2. Within 1 month or have within 5 half-lives (whichever is longer) participated in any trail (defined participate in trail as having had randomized) of using drug or therapy prior to screening.
  1. General information:
  1. Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent nicotine per day).
  2. Previous participation in this study. Participation was defined as randomised.
  1. Any other situation judged by investigator that may endanger the safety of the subjects or influence the evaluation of the results.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Arm 1: Medication regimen A-B-C

    Drug: HR011408 injection; HR011408 injection Placebo · Drug: NovoRapid®; HR011408 injection Placebo · Drug: HR011408 injection Placebo; HR011408 injection

  • Experimental
    Arm 2: Medication regimen B-C-A

    Drug: HR011408 injection; HR011408 injection Placebo · Drug: NovoRapid®; HR011408 injection Placebo · Drug: HR011408 injection Placebo; HR011408 injection

  • Experimental
    Arm 3: Medication regimen C-A-B

    Drug: HR011408 injection; HR011408 injection Placebo · Drug: NovoRapid®; HR011408 injection Placebo · Drug: HR011408 injection Placebo; HR011408 injection

Interventions

  • DrugHR011408 injection; HR011408 injection Placebo

    Medication regimen-A: HR011408 injection, ante cibum; HR011408 injection Placebo , post cibum

  • DrugNovoRapid®; HR011408 injection Placebo

    Medication regimen-B: NovoRapid®, ante cibum; HR011408 injection Placebo, post cibum

  • DrugHR011408 injection Placebo; HR011408 injection

    Medication regimen-C: HR011408 injection Placebo, ante cibum: HR011408 injection, post cibum

06

What researchers measure

Primary outcomes

  1. Area under the serum concentration-time curve of insulin aspart

    Time frame: From 0 to 30 mins after trial product administration

Secondary outcomes

  1. Area under the serum concentration-time curve of insulin aspart

    Time frame: From 0 to 6 hours after trial product administration

  2. Plasma glucose concentration

    Time frame: From 0 to 6 hours after start of a standardised meal

  3. Number of subjects with adverse events and severity of adverse events

    Time frame: From first dose to the last visit, approximately 2 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2024; primary completion for Jul 2024, 2 months later.

Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's planned 2 months is below that.

Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2024
First posted
Apr 19, 2024
StartEst.
May 2024
Primary completionEst.
Jul 1, 2024
CompletionEst.
Jul 15, 2024
Last update
May 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06375031
Responsible party
Sponsor
First posted
Apr 19, 2024
Start date
May 2024 (estimated)
Primary completion
Jul 1, 2024 (estimated)
Completion
Jul 15, 2024 (estimated)
Last update
May 21, 2024

Study contacts

Hong Chen
Contact
hong.chen@hengrui.com
+86-0518-82342973
Yifan Li
Contact
yifan.li@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion